Overview of study methodology within each nation
| England (cohorts 1 and 4) | Wales (cohorts 2 and 5) | Northern Ireland (cohorts 2 and 5) | Scotland (cohorts 2 and 5) | Normative study (cohort 3) | |
|---|---|---|---|---|---|
| Data source | Cancer registry | Cancer registry | Cancer registry | Hospital admissions | BSO |
| Confirmation of diagnosis and eligibility | Prostate MDT lead | Prostate MDT lead | Prostate MDT lead plus nurse check for unstaged cases | Hospital admission for prostate cancer plus cancer registration in relevant time period | |
| Exclusions | Men eligible for NPCA /true NTH | Men eligible for NPCA | List from protocol | Men with previous prostate cancer | |
| Death checks | NHS Digital | NHS Digital | BSO | NRS/NHSCR/CHI | BSO |
| Survey mail-out | Picker | Picker | Cancer registry | Picker | Picker |
| Language | English | English/Welsh | English | English | |
| Survey dates | Cohort 1: November 2015–February 2016 Resurvey: November 2016–February 2017 Cohort 4: January 2017–March 2017 | Cohort 2: June 2016–August 2016 Resurvey: June 2017–August 2017 Cohort 5: January 2017–March 2017 | May 2016–July 2016 | ||
| Estimated survey numbers* | Cohort 1: n=60 000 Resurvey: n=42 000 Cohort 4: n=15 000 | Cohort 2: n=4000 Resurvey: n=2800 Cohort 5: n=2000 | Cohort 2: n=2000 Resurvey: n=1400 Cohort 5: n=1000 | Cohort 2: n=3600 Resurvey: n=2500 Cohort 5: n=1800 | n=4000 |
| Data linkages | Cancer registration; hospital admissions; radiotherapy; patient experience survey; end-of-life care | Cancer registration; hospital admissions; radiotherapy | Cancer registration; hospital admissions; radiotherapy | Cancer registration; hospital admissions; radiotherapy (linkage will only be possible where responding patients have given their consent) | |
| Telephone interviews | Cohort 1: n=120 Follow-up interviews: n=60 | Cohort 2: n=20 | Cohort 2: n=20 | Cohort 2: n=20 | Not applicable to this cohort |
*Estimates represent the total number of men eligible for inclusion (before death checks); resurvey estimates are based on a 70% response to first surveys.